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outcomes and an unquestioned insistence on reducing Type 
1 errors regardless of the research context. Rigidity in 
research infrastructure focuses on the unquestioned valid-
ity of patient input on scientific matters, and increasingly 
rigid guidelines and checklists that end up driving grant 
applications.
Discussion It is hoped that this overview will lead to a 
reconsideration of a more flexible application of research 
principles while retaining scientific rigor.
Keywords Quality of life · Research principles · 
Research cycle · Guidelines · Overview
Introduction
“The enemy of science is not religion …
The true enemy is the substitution of thought, reflec-
tion, and curiosity with dogma.”
Excerpt from The Bonobo and the Atheist by Frans 
de Waal, 2013 [1].
Over the course of professional training, researchers have 
been taught rigorous research methods. Some are context 
specific while others are facilitated and enhanced by guide-
lines and protocols that are based on shared values, i.e. sets 
of beliefs about good and bad research, and research prin-
ciples, i.e., rules about how to conduct good research. The 
availability of a myriad of such resources is a reflection of 
the maturation of the field of quality-of-life (QOL) research. 
While these guidelines and protocols are helpful, we note 
that they can take on a prominence that can undermine our 
research. An automatic or ‘unmindful’ application of these 
value-based research principles can indeed become dog-
matic, and may limit the impact of QOL research. At the 
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Background The field of quality-of-life (QOL) research 
has matured into a discipline with scientific rigor, sophis-
ticated methods, and guidelines. While this maturation 
is laudable and needed, it can result in a limiting rigidity. 
We aim to highlight examples of practices that are based 
on shared research values and principles that, when dog-
matically applied, may limit the potential impact of QOL 
research.
Methods By juxtaposing rigorous standards with their 
rigid application for different stages of the research cycle, 
we suggest more balanced approaches.
Results Rigidity in cultivating a research question relates 
to constraining our thinking, leading to ‘safe’ research 
focusing on small variations of similar studies. Rigidity in 
operationalizing key constructs focuses on problems with 
validation practices that hinder further innovations, the use 
of static questionnaires when a more flexible approach is 
needed, dismissing rarely endorsed items that are clini-
cally relevant, use of insensitive generic measures when 
specific measures are required, and a rigid emphasis on 
short questionnaires. Rigidity in data analysis relates to 
an undue emphasis on delineating primary and secondary 
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very soul of scientific inquiry, ‘discovery’ or progress can-
not be achieved by blindly following prescriptive scientific 
methods or just following what has already been established 
[2, 3]. We aim to highlight examples from different stages of 
the research cycle and to suggest more balanced approaches. 
While some dogmatic applications are more pronounced, 
others are less obvious. We also notice more frequent dog-
matic applications in some phases of the research cycle 
(e.g., operationalization) than in others (e.g., analysis). Our 
ultimate goal is to encourage more sensible and flexible 
applications of research principles in practice while retain-
ing scientific rigor.
Rigor versus rigidity in cultivating a research question
Most research is iterative, with small leaps forward that 
build on and acknowledge past research and inspiration. As 
a consequence, reviewers and editors require that we ref-
erence precedent papers for the rationales of our studies. 
When rigidly applied, ‘safe’ research would focus on repli-
cations or small variations of the same study (‘me-too stud-
ies’). Examples are the description of QOL in yet another 
specific disease population or validation studies of the 
same questionnaire in different languages and countries.
True replication studies are needed to solidify the field, but 
they are rare, such as cross-validation studies of the struc-
tural validity or measurement invariance of widely used 
QOL questionnaires. When publications claim to address 
new concepts they more often than not ‘sell old wine in 
new bottles’, frequently because their literature search did 
not extend beyond their own specific niche. For example, 
measures are published each year that are claimed to be 
‘new’, but rarely address new concepts not already assessed 
by previously published instruments. A more extreme dog-
matic application that we have witnessed in research team 
discussions and as reviewers is that thinking can be con-
strained to only that which can be referenced by another 
published work in one’s own niche. It is unfortunate that 
the resulting iterative studies are generally more easily 
accepted for publication than unconventional and possi-
bly seminal work, particularly if it challenges widely held 
beliefs. A more balanced approach would allow for new 
thinking that may not have a reference to prior work, i.e., 
paradigm shifts and other innovations, in addition to pursu-
ing more main-stream studies based on ample references. 
Fortunately, established journals are increasingly creating 
platforms that explicitly encourage such new thinking.
Similarly, most would agree that any review of the lit-
erature must be up-to-date with the latest findings. A draw-
back of the more rigid application of this principle is that 
research papers often focus exclusively on recent papers. 
We would argue that a review of the literature should 
include relevant papers, including seminal papers of old (do 
not reinvent the wheel) and hot off-the-press papers (stay 
current). While this may seem self-evident, we recurrently 
find ourselves, as a reviewer or editor, alerting authors to 
(seminal) papers that are missing from the introduction 
or discussion sections. By balancing more and less recent 
papers, the authors are acknowledging original work, high-
lighting possibly neglected ideas that may deserve more 
attention, providing a historical background, and enhanc-
ing our understanding of the field. We would also encour-
age acknowledging the inspiration by other authors, refer-
encing personal communication and referring to relevant 
research in other areas of expertise. Such practices will 
likely advance our field.
Rigor versus rigor mortis in operationalizing key 
constructs
A strong research principle is that measures should be vali-
dated to ascertain their psychometric integrity and facilitate 
comparability across studies over time. A related principle 
is the need to improve the validity of such measures via 
revisions. Validation studies often reveal minor limitations 
of the measure. However, the implementation and com-
puting costs are often substantial, reporting and keeping 
track of the different versions problematic, and the fear of 
compromising the comparability across studies paralyz-
ing. Thus, tweaking the measure in accordance with the 
published limitations is rarely feasible. A dogmatic albeit 
common practice is to adhere to the measure as originally 
validated, thereby letting the limitations fester quietly in the 
discussion sections with no improvements made.
Interestingly, validation of a measure is meant to be a 
multi-dimensional and iterative process until it yields suffi-
cient levels of the desired aspect of validity (e.g., content or 
criterion validity). Yet, we often see ‘validity’ discussed as 
if it were a single, dichotomous construct. A measure is 
valid or not; a measure is never described as valid for 80 or 
47%. Moreover, textbooks [4] and widely adopted guide-
lines [5] ascertain that a single study does not prove a 
measure to be ‘valid in general’, but for a specific purpose 
in a specific sample. A specific measure’s few validation 
papers are referenced to legitimize its further use in appli-
cations for which it was not originally validated. Thus, 
treating validation like a dichotomous construct allows us 
to say a measure yields ‘good validity’, and creates a belief 
in a tool irrespective of its application. This practice hin-
ders further innovations. This ‘ritual dance of validation’1 
1 The term ‘ritual dance of validation’ is not ours. MAGS heard it 
once during a lecture that she thinks Peter Fayers held. When asked, 
Peter could not remember having used this term. If someone recog-
nizes it as his/hers, please accept our sincere apologies for not refer-
encing appropriately and let us know who you are.
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needs to be replaced by a more flexible validation practice 
paying credit to both rigor and adaptability.
For example, the accelerated release of targeted thera-
pies with varying toxicity profiles demands such flexibility. 
Adaptive clinical trial designs are increasingly being used 
with the aim to more quickly identify drugs with therapeu-
tic effect. In such designs the protocol is modified (e.g., 
dosing levels) throughout the trial, based on observations. 
The sole use of static, standardized questionnaires may fail 
to ensure content validity in those new clinical trials [6]. 
These measures need to be supplemented with specific 
questions relevant to the trial phase. Current discussions in 
cooperative groups and the United States (US) Food and 
Drug Administration (FDA) are even leaning toward a 
modifiable, ‘à la carte’2 approach to QOL measurement for 
efficacy trials. For example, patients might be asked differ-
ent questions on-treatment than during follow-up [7]. Pay-
ing more attention to flexibility and clinical relevance will 
likely make the validation process less ceremonial and 
enhance its meaningfulness.
Related to the issue of clinical relevance, we note the 
dilemma of rarely endorsed items in patient-reported out-
come tools. While it is true that measurement validation 
approaches in classical test theory analyses work better 
when items are not skewed, dropping rarely endorsed items 
(i.e., skewed) has a cost. It has been documented that dis-
missing rarely endorsed items can reduce the ability of a 
measure to detect important differences between subgroups 
or identify clinical syndromes. For example, about half of 
the items in the Missoula-Vitas Quality of Life Index are 
highly skewed, suggesting rare endorsement. Its factor 
structure is unstable across illness groups and its inter-
nal-consistency reliability scores are low [8]. These poor 
psychometric indicators coupled with its highly rated rel-
evance from both patients and healthcare providers sug-
gest that the tool serves a useful clinical function but it is 
not feasible as a psychometric outcome measure [8]. The 
shared value that we need reliable instruments, particularly 
when used as primary endpoints or as the basis for deci-
sion-making, may turn into a rigid neglect of their clini-
cal relevance. Therefore, rarely endorsed items should be 
examined and retained if clinically or scientifically impor-
tant. An acknowledged caveat of keeping those items is that 
they cannot be retained in a subscale as they would reduce 
its internal consistency reliability, and thus would be ana-
lyzed as single items at the cost of lower reliability.
A sign of success for our field is that there are widely 
accepted standards for the collection and reporting of 
QOL by regulatory agencies, e.g., FDA [9], and by the 
National Institutes of Health (NIH) [10]. Moreover, 
2 The term ‘à la carte’ approach to QOL measurement was coined by 
Corneel Coens.
recommendations for incorporating QOL in prospective 
comparative effectiveness studies (e.g., clinical trials) have 
been established [11]. It is generally acknowledged that 
generic measures lack the sensitivity to detect differences 
in toxicity profiles and side effects between treatment arms. 
This insight led to the development of disease-specific 
questionnaires [4]. Nonetheless, there are still trials that 
only employ generic measures [12]. This trend does not 
belong to the past; we currently witness the same practice 
as committee members reviewing trial protocols. Moreover, 
whereas European Organisation for Research and Treat-
ment of Cancer (EORTC) clinical trials consistently admin-
ister the core Quality of Life Questionnaire (QLQ-C30), 
they rarely implement site- and treatment-specific mod-
ules because their specialized nature is more difficult to fit 
into trial objectives [7]. A related trend is the predilection 
toward generic or “off-the-shelf” QOL assessments where 
a clinical trial team can simply download a standard ques-
tionnaire or template with guidelines and insert it in the 
protocol [7]. Whereas generic measures have some advan-
tages, they may risk missing the difference across disparate 
therapies [6]. Further, using solely generic measures back-
fires on our field; it has led to the idea that assessing QOL 
in clinical trials is not needed since it does not make a dif-
ference. Using such generic measures exclusively may be a 
halfhearted compromise to address QOL. It is also a sign 
of undue reliance on measures validated in another context 
at the cost of ensuring content validity. It is akin to the par-
able of the person who looks for lost keys under the street 
light rather than where he lost them. It is better to supple-
ment generic measures with content-valid QOL questions. 
Calibrated item banks (e.g., [13]), may also be useful as 
they cover the entire spectrum of functioning or symptom 
experience. However, they may not include all the domains 
needed for specific trials. Whether existing or new, one 
should select questions that are most likely to reveal clini-
cally important differences between treatment arms based, 
at a minimum, on their toxicity profiles.
While content-valid measurement is a long-held goal, it 
is often counteracted by a concern about excessive patient 
burden as, in general, the longer the questionnaire, the 
lower the response rate [14]. Our experience is that grant 
reviewers, ethics committees and clinicians alike resist 
study protocols with numerous questionnaires. They state 
that the perceived patient burden and the resulting risk of 
low-quality data outweigh the need for measuring theo-
retically or clinically relevant constructs. This focus on 
short questionnaires might be a sign of a latent mistrust 
of questionnaire data: “OK, we do not really think that 
this will show anything of importance, so please make it 
quick.” This attitude is in marked contrast to entire fields 
of research (e.g., psychology) or even FDA guidelines that 
require high-quality assessments of subjective experiences. 
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A common research practice is to limit the questionnaire 
to a 10–15 min completion time for clinical trials [11] to 
ensure participant compliance and few missing data. Such 
a general rule of thumb does not exist for standalone stud-
ies. Clearly, computer adaptive testing or IRT-based short 
forms allow for administering only relevant and fewer items 
without losing scientific rigor. Nonetheless, many stud-
ies require longer questionnaires. The experience of many 
researchers is that long questionnaires can be successfully 
implemented if the respondents are interested and engaged 
in the topics [15–18]. In fact, patients often welcome QOL 
questionnaires as a sign of interest in life aspects that mat-
ter to them [19]. Moreover, longer questionnaires are more 
feasible if data collection approaches are used that allow 
participants to ‘save and continue’ [20]. In the US, study 
participants are generally more willing to spend time com-
pleting long questionnaires if they are paid for their time 
[20], although cancer patients were found to be unwilling to 
complete long questionnaires even when paid [21]. Special 
attention should be devoted to explaining possible redun-
dancy in a questionnaire that consists of multiple instru-
ments, e.g., when similar questions are asked by different 
instruments [20]. A careful explanation why this redun-
dancy is necessary will likely increase patients’ motivation 
[20].
Mindfulness in data analysis
Two other research principles are that statistical power 
considerations require the distinction between primary and 
secondary outcomes in testing a priori hypotheses and that 
statistical testing should limit false rejection of the null 
hypothesis (Type 1 error). The corollary is the requirement 
to adjust for multiple comparisons [22] and false discovery 
rates [23]. Unfortunately, insufficient emphasis on Type 1 
error is a recurrent research practice. For example, when an 
effectiveness study of a psychosocial or medical interven-
tion results in an insignificant primary outcome, research-
ers too frequently seek and publish significant results 
from outcomes and subgroups that were not pre-specified, 
thereby ignoring the risk of false-positive results. This 
insipid research practice is often done with the excuse that 
the analyses are “exploratory”. However, publications of 
randomized clinical trial results are expected to pay credit 
to Type 1 errors, with prior publication of trial protocols 
being increasingly required and the establishment of clini-
cal trial units with biostatisticians on board. Conversely, in 
the context of genuine, exploratory or descriptive research, 
a rigid emphasis on reducing Type I error may be self-
limiting [24]. In those cases, we would argue that one 
should allow for the possibility that a research study has 
value by describing findings across a range of outcomes 
and reporting the effect size estimates. By the same token, 
publications of non-significant (replication) findings are 
needed to build an evidence-based body of research [25].
Fashion versus fusion in shared perspectives
The long-held core value that QOL is inherently subjec-
tive gains prominence in an increasingly patient-centered 
health care environment. Our measures amplify the patient 
perspective. If a patient and a proxy diverge in assessing 
the patient’s QOL, it is almost a moral imperative that 
the patient is ‘right’. For example, discrepancies between 
patient-proxy ratings are interpreted, a priori, as evidence 
of the inaccuracy or biased nature of proxy-generated data, 
even if the patient is intellectually impaired [26]. However, 
the level of patient-proxy agreement is also influenced 
by methodological and psychometric factors. Moreover, 
patient ratings, such as proxy ratings, may be subject to 
biases [27]. While a large body of research has shown that 
both patients and proxies can provide relevant and comple-
mentary information about QOL [28, 29], it is less fash-
ionable to consider other uses of proxy assessment. Espe-
cially for the physical QOL domain, an exclusive reliance 
on patient reports might signify procedural rigidity instead 
of conceptual rigor. For example, the doctors’ perspective 
on the patient’s symptom experience can serve as a useful 
benchmark for an individual’s symptom experience relative 
to others with a similar condition, given their witnessing 
the entire spectrum of patients. Further, patient-proxy con-
gruence can be used as an indicator of intimacy or social 
connectedness [30] and thus can be a helpful outcome for 
behavioral intervention studies [31].
Consciousness in maintaining the research 
infrastructure
Thus far we have addressed the research cycle, but before 
research can even begin one must seek funding. In response 
to calls for increasing transparency, grant funding agencies 
adopt grant proposal forms and evaluation criteria that are 
as specific and uniform as possible. This laudable egali-
tarian approach has, however, led to the increasing use of 
rigid time-consuming guidelines and checklists that end 
up driving grant applications (i.e., the forms seem to take 
precedence over the science). The shared values of objec-
tivity and comparability seem to have turned into bureau-
cratic rigidity. Academic research is increasingly depend-
ent on external funding and the probability of getting that 
funding is often less than 10%. Hence, researchers must 
devote an arduous amount of time to grant writing despite a 
very low likelihood of funding. This is a waste of precious 
resources that most researchers acknowledge but feel pow-
erless to change.
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We would urge a fundamental change in the nature of 
grant proposals. Particularly, in Europe, sponsors increas-
ingly require a relatively brief concept statement (one to 
three pages) as an initial submission. Similar to the sim-
pler approach taken by pharmaceutical companies in fund-
ing academic research, we would suggest that if and only 
if this concept is compelling and likely to be funded, the 
researchers should continue. The further fleshing out of 
the proposal as well as supporting documentation would 
then be done in an iterative but brief manner to negotiate 
approaches (i.e., back-and-forth communication) that inte-
grate the sponsor’s mission. The resulting funding agree-
ment would allow the researcher ‘wiggle room’ to figure 
out the best study procedures while keeping the sponsor 
apprised of the study’s progress. We believe that embracing 
the ‘speed of trust’ [32] is not only more considerate but 
will result in a better use of resources.
Review committees are also key to funding. It is increas-
ingly acknowledged that patients have a unique understand-
ing of their disease, which should not only be integrated 
at each stage of the research cycle, but also at the stage 
of reviewing grant proposals. Their input can be particu-
larly cogent in assessing the study’s relevance and real-life 
impact the research outcome will have. The above-men-
tioned moral imperative can also lead to the unquestioned 
validity of patient input on scientific matters when included 
as reviewers for funding bodies. While we do not dispute 
the importance of real-life experience informing patients’ 
desired subjective input, it should be carefully considered 
with the same caveats as that of any other stakeholder.
Going forward
Awareness can be a first step toward change. We would 
like to emphasize that guidelines and checklists are helpful 
heuristics, not irrefutable prescriptions. Shared values and 
research principles may turn rigor into rigidity when they 
are applied unmindfully. We hope that this brief discussion 
of current trends will stimulate discussion and serve as a 
reminder to facilitate a more flexible application of research 
principles in practice while keeping scientific rigor.
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